These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30605829)

  • 21. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):651-656. PubMed ID: 29536777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Zheng N; Pan J; Hao Q; Li Y; Zhou W
    Bioorg Med Chem; 2018 May; 26(8):2165-2172. PubMed ID: 29567295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
    Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
    Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
    Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
    Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel pyrido[3,2-d]pyrimidine derivatives as selective and potent PI3Kδ inhibitors.
    Bai H; Sun J; Lei H; Zhang SQ; Yuan B; Ma M; Xin M
    Drug Dev Res; 2023 Dec; 84(8):1709-1723. PubMed ID: 37732677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Tang Y; Zheng Y; Hu X; Zhao H; Cui S
    J Med Chem; 2024 Apr; 67(8):6638-6657. PubMed ID: 38577724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
    Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
    Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
    Wu H; Hu C; Wang A; Weisberg EL; Chen Y; Yun CH; Wang W; Liu Y; Liu X; Tian B; Wang J; Zhao Z; Liang Y; Li B; Wang L; Wang B; Chen C; Buhrlage SJ; Qi Z; Zou F; Nonami A; Li Y; Fernandes SM; Adamia S; Stone RM; Galinsky IA; Wang X; Yang G; Griffin JD; Brown JR; Eck MJ; Liu J; Gray NS; Liu Q
    Leukemia; 2016 Jan; 30(1):173-81. PubMed ID: 26165234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
    Niemann CU; Mora-Jensen HI; Dadashian EL; Krantz F; Covey T; Chen SS; Chiorazzi N; Izumi R; Ulrich R; Lannutti BJ; Wiestner A; Herman SEM
    Clin Cancer Res; 2017 Oct; 23(19):5814-5823. PubMed ID: 28645939
    [No Abstract]   [Full Text] [Related]  

  • 30. Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation.
    Tao Q; Chen Y; Liang X; Hu Y; Li J; Fang F; Wang H; Meng C; Liang J; Ma X; Gui S
    Eur J Med Chem; 2020 Apr; 191():112143. PubMed ID: 32078865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
    Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
    Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies.
    Liu X; Wang A; Liang X; Liu J; Zou F; Chen C; Zhao Z; Deng Y; Wu H; Qi Z; Wang B; Wang L; Liu F; Xu Y; Wang W; Fernandes SM; Stone RM; Galinsky IA; Brown JR; Loh T; Griffin JD; Zhang S; Weisberg EL; Zhang X; Liu J; Liu Q
    Oncotarget; 2016 Aug; 7(33):53515-53525. PubMed ID: 27447747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of AS2541019, a novel selective PI3Kδ inhibitor, on antibody production and hamster to rat xenotransplantation.
    Marui T; Fukahori H; Kawashima T; Ito M; Akamatsu M; Kaneko Y; Takahashi F; Imada S; Morokata T
    Eur J Pharmacol; 2018 May; 826():179-186. PubMed ID: 29518396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives.
    Chand K; Prasad S; Tiwari RK; Shirazi AN; Kumar S; Parang K; Sharma SK
    Bioorg Chem; 2014 Apr; 53():75-82. PubMed ID: 24632506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies.
    Zhang J; Jiang H; Lin S; Wu D; Tian H; Jiang L; Cui Y; Jin J; Chen X; Xu H
    J Med Chem; 2022 Jun; 65(11):8011-8028. PubMed ID: 35609190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors.
    Lin TE; Sung LC; Chao MW; Li M; Zheng JH; Sung TY; Hsieh JH; Yang CR; Lee HY; Cho EC; Hsu KC
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):226-235. PubMed ID: 34894949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
    Xue Y; Song P; Song Z; Wang A; Tong L; Geng M; Ding J; Liu Q; Sun L; Xie H; Zhang A
    J Med Chem; 2018 May; 61(10):4608-4627. PubMed ID: 29715023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling.
    Mera WA; Alzihlif M; Taha MO; Khanfar MA
    Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
    Ge Y; Wang C; Song S; Huang J; Liu Z; Li Y; Meng Q; Zhang J; Yao J; Liu K; Ma X; Sun X
    Eur J Med Chem; 2018 Jan; 143():1847-1857. PubMed ID: 29146136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
    Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.